Structured treatment interruptions in antiretroviral management of HIV-1

Current Opinion in Infectious Diseases

Volumn 14, Issue 1, 2001, Pages 29-37

  Miller, V ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ANTIMICROBIAL THERAPY; CLINICAL TRIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; LYMPHOCYTE COUNT; MULTICENTER STUDY; MULTIDRUG RESISTANCE; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS IMMUNITY; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 0035146527     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200102000-00006     Document Type: Review

References (71)

1. Control of HIV despite the discontinuation of antiretroviral therapy
2. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure
3. Virologic and immunologic evaluation of structured treatment interruptions in patients experiencing long-term virologic failure
4. Reservoirs dog AIDS therapy
5. Metabolic and morphologic complications of HIV
6. Emerging complications: Mitochondrial toxicity, lipoatrophy and bone changes
7. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
8. Coverage, adherence, and sustainability of antiretroviral therapy among injection drug users in Vancouver, Canada
9. Rethinking nonadherence: Historical perspectives on triple-drug therapy for HIV disease
10. Antiretroviral treatment initiative in Senegal: Results on treatment observance from a study conducted at the pharmacy
11. Vigorous HIV-1 specific CD4+ T cell responses associated with control of viremia
12. HIV type 1-specific helper T cells: A critical host defense
13. HIV-1 specific immune responses in subjects who temporarily contain antiretroviral therapy
14. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy
15. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses
16. HIV-1 specific CD4 T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
17. Discontinuation of therapy after treatment for primary HIV infection (PHI)
18. Virologic and immunologic profiles of newly infected individuals electing discontinuation of HAART after approximately three years of apparently suppressive therapy
19. Viral load rebound upon discontinuation of d4T + ddl + NVP with or without hydroxyurea (HU) during primary HIV infection (PHI)
20. Discontinuation of HAART after a course of therapeutic vaccination with ALVAC 1452 and rgp160 may be associated with delayed viral rebound kinetics
21. Increase in breadth and frequency of CTL responses following structured therapy interrutions in individuals treated with HAART during acute HIV-1 infection
22. Immune control of HIV-1 after early treatment of acute infection
23. Stable peripheral blood HIV-1 reservoirs following structured therapy interruptions (STI) in two subjects
24. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment
25. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy
26. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression
27. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy
28. HIV-1 and T-cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
29. Rapid activation of lymph nodes and mononuclear cell HIV expression upon interrupting highly active antiretroviral therapy in patients after prolonged viral suppression
30. Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy
31. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption
32. Hidden HIV-1 drug resistance mutations appear during sequential cycles of structured treatment interruptions in HIV-1-infected patients with long-term viral suppression (AutoVac study)
33. Continuous and spontaneous control of plasma viral load after 8 months without antiretroviral therapy and three cycles of structured therapy interruption in chronic HIV-1 infection. Correlation with induced cytotoxic and helper HIV-1 specific immune responses
34. Hydroxyurea neither prevents viral load rebound nor facilitates further control of viral replication after three consecutive cyclic interruptions of therapy in chronic HIV infection: A randomized trial
35. Rapid rebound of viral replication, T cell activation, proliferation and dysfunction after discontinuation of HAART with or without interleukin 2
36. The Swiss-Spanish Intermittent Trial (SSITT)
37. Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression
38. No detectable HIV RNA in thirteen individuals months after stopping antiretroviral therapy
39. Plasma HIV after therapy interruption
40. Control of viremia after treatment interruption
41. Success of structured treatment interruptions (STI) in chronically infected patients depends on the antiretroviral regimen
42. Cessation of HAART plus daily low-dose interleukin 2 to promote immunity to HIV
43. Structured antiviral treatment interruption followed by daily low dose interleukin 2 (IL-2) reveals immune response to HIV
44. Significant delay in plasma vRNA rebound during a scheduled treatment interruption in HIV-1 chronically infected patients previously on effective therapy
45. A controlled trial of treatment interruption in chronically HIV-infected subjects
46. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy
47. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression
48. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active antiretroviral therapy
49. Hydroxyurea and didanosine long-term treatment prevents breakthrough and normalizes immune parameters
50. A randomized, controlled trial of intermittent versus continuous highly active antiretroviral therapy (HAART)
51. Short cycle intermittent HAART: A pilot study
52. Intermittent interruptions of antiretroviral therapy in chronically HIV-infected patients do not induce immune control of HIV
53. Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load
54. Reroviral rebound syndrome after cessation of suppressive antiretroviral therapy in three patients with chronic HIV infection
55. Psychological impact of intermittent treatment interruptions in patients with non-detectable HIV-1 viral load
56. Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection
57. Antiretroviral treatment interruptions in patients with treatment failure: Analysis from the Frankfurt HIV Cohort
58. Concomitant overgrowth of drug-resistant HIV-1 in CSF and plasma during treatment interruption after long-term virological failure
59. Resistance and virological evaluation of structured treatment interruption in 20 heavily experienced patients harbouring long-term therapeutic failure (GENOSTOP pilot study)
60. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy
61. Patients' characteristics and genotype resistance pattern when stopping therapy for drug resistance
62. Mega-HAART, resistance and drug holidays
63. Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens
64. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype
65. Reappearance of wild-type HIV-1 strains after antiretrovirals interruption in heavily treated patients
66. Early reappearance of multidrug resistance mutations after structured treatment interruption
67. Kinetics of the genotypic switch from mutant to wild-type virus during structured treatment interruptions analysed by an ultra-sensitive detection
68. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection
69. Virological and immunological characteristics of HIV treatment failure
70. High levels of drug resistant human immunodeficiency virus variants in patients exhibiting increasing CD4+ T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy
71. The impact of protease inhibitor-containing HAART on progression of HIV disease and its relationship to CD4 and viral load